Dec 2022 $28 M Issued in a merger or acquisition $10 to $50 million 5
Muse Biotechnology, Inc.: Private sale, Dec 2022 × Investors in this round 5 investors had bought by the notice of Jan 18, 2023: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $28 M of $28 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Justin Ferber · Executive Officer Ron McGrath · Executive Officer Sri Kosaraju · Executive Officer, Director Bryan L. Roberts · Director John R. Stuelpnagel · Director Kristala L. Jones Prather · Director Roger R. Wyse · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 18, 2023. Read the notice at the SEC .
equity, options SEC Dec 2022 $4 M Issued in a merger or acquisition $2 to $10 million 4
Muse Biotechnology, Inc.: Private sale, Dec 2022 × Investors in this round 4 investors had bought by the notice of Jan 18, 2023: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $4 M of $4 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Justin Ferber · Executive Officer Ron McGrath · Executive Officer Sri Kosaraju · Executive Officer, Director Bryan L. Roberts · Director John R. Stuelpnagel · Director Kristala L. Jones Prather · Director Roger R. Wyse · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 18, 2023. Read the notice at the SEC .
equity SEC Nov 2021 $2 M No. 10 Under $2 million 2
Muse Biotechnology, Inc.: Raise no. 10, Nov 2021 × Investors in this round 2 investors had bought by the notice of Jun 1, 2023: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Justin Ferber · Executive Officer Sri Kosaraju · Executive Officer, Director Bryan L. Roberts · Director John R. Stuelpnagel · Director Kristala L. Jones Prather · Director Roger R. Wyse · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.”Signed by Justin Ferber, General Counsel. Source: SEC Form D, newest notice filed Jun 1, 2023. Read the notice at the SEC .
options SEC Mar 2021 $150 M No. 9 $50 to $250 million 32
Muse Biotechnology, Inc.: Raise no. 9, Mar 2021 × Investors in this round 32 investors had bought by the notice of Apr 14, 2021: 32 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $150 M of $150 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna L. DeVore · Executive Officer Michael R. Graige · Executive Officer Ron R. McGrath · Executive Officer Sri Kosaraju · Executive Officer, Director Bryan L. Roberts · Director John R. Stuelpnagel · Director Roger R. Wyse · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Apr 14, 2021. Read the notice at the SEC .
equity SEC Nov 2020 $50 M No. 8 $50 to $250 million 6
Muse Biotechnology, Inc.: Raise no. 8, Nov 2020 × Investors in this round 6 investors had bought by the notice of Nov 30, 2020: 6 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna L. DeVore · Executive Officer Michael R. Graige · Executive Officer Ron R. McGrath · Executive Officer Sri Kosaraju · Executive Officer, Director Bryan L. Roberts · Director John R. Stuelpnagel · Director Roger R. Wyse · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 30, 2020. Read the notice at the SEC .
equity SEC Oct 2020 $8 M No. 7 $2 to $10 million 1
Muse Biotechnology, Inc.: Raise no. 7, Oct 2020 × Investors in this round 1 investor had bought by the notice of Nov 30, 2020: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $8 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna L. DeVore · Executive Officer Michael R. Graige · Executive Officer Ron R. McGrath · Executive Officer Sri Kosaraju · Executive Officer, Director Bryan L. Roberts · Director John R. Stuelpnagel · Director Roger R. Wyse · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.”Signed by Sri Kosaraju, Chief Executive Officer. Source: SEC Form D, newest notice filed Nov 30, 2020. Read the notice at the SEC .
options SEC Nov 2019 $92 M No. 6 $50 to $250 million 12
Muse Biotechnology, Inc.: Raise no. 6, Nov 2019 × Investors in this round 12 investors had bought by the notice of Dec 11, 2019: 12 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $92 M of $125 M offered; $33 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna D. DeVore · Executive Officer Jason T. Gammack · Executive Officer Kevin D. Ness · Executive Officer, Director Michael T. Graige · Executive Officer Ron T. McGrath · Executive Officer Bryan D. Roberts · Director John R. Stuelpnagel · Director Roger R. Wyse · Director Andrew D. Garst · Promoter Ryan T. Gill · Promoter Tanya T. Lipscomb · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 11, 2019. Read the notice at the SEC .
equity SEC Jan 2019 $50 M No. 5 $50 to $250 million 14
Muse Biotechnology, Inc.: Raise no. 5, Jan 2019 × Investors in this round 14 investors had bought by the notice of Apr 15, 2019: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna D. DeVore · Executive Officer Jason T. Gammack · Executive Officer Kevin D. Ness · Executive Officer, Director Michael T. Graige · Executive Officer Bryan D. Roberts · Director John R. Stuelpnagel · Director Roger R. Wyse · Director Andrew D. Garst · Promoter Ryan T. Gill · Promoter Tanya T. Lipscomb · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Apr 15, 2019. Read the notice at the SEC .
equity SEC Aug 2018 $1 M Issued in a merger or acquisition Under $2 million 9
Muse Biotechnology, Inc.: Private sale, Aug 2018 × Investors in this round 9 investors had bought by the notice of Sep 17, 2018: 9 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna D. DeVore · Executive Officer Kevin D. Ness · Executive Officer, Director Bryan D. Roberts · Director John R. Stuelpnagel · Director Roger R. Wyse · Director Andrew D. Garst · Promoter Ryan T. Gill · Promoter Tanya T. Lipscomb · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 17, 2018. Read the notice at the SEC .
equity SEC Feb 2018 $56 M No. 4 $50 to $250 million 14
Muse Biotechnology, Inc.: Raise no. 4, Feb 2018 × Investors in this round 14 investors had bought by the notice of Mar 7, 2018: 14 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $56 M of $56 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna R. DeVore · Executive Officer Kevin D. Ness · Executive Officer, Director Ryan T. Gill · Executive Officer, Director, Promoter Tanya T. Lipscomb · Executive Officer, Promoter Bryan D. Roberts · Director John R. Stuelpnagel · Director Roger T. Wyse · Director Andrew D. Garst · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 7, 2018. Read the notice at the SEC .
equity SEC Feb 2017 $23 M No. 3 $10 to $50 million 10
Muse Biotechnology, Inc.: Raise no. 3, Feb 2017 × Investors in this round 10 investors had bought by the notice of Mar 1, 2017: 10 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $23 M of $23 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Kevin D. Ness · Executive Officer, Director Ryan T. Gill · Executive Officer, Director, Promoter Bryan D. Roberts · Director Eric T. Moessinger · Director John D. Stuelpnagel · Director Roger T. Wyse · Director Andrew D. Garst · Promoter Tanya T. Lipscomb · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 1, 2017. Read the notice at the SEC .
equity SEC Nov 2016 $1 M No. 2 Under $2 million 1
Muse Biotechnology, Inc.: Raise no. 2, Nov 2016 × Investors in this round 1 investor had bought by the notice of Mar 7, 2018: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $1 M of $1 M offered
Smallest investment taken no minimum stated
What was sold options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Dianna R. DeVore · Executive Officer Kevin D. Ness · Executive Officer, Director Ryan T. Gill · Executive Officer, Director, Promoter Tanya T. Lipscomb · Executive Officer, Promoter Bryan D. Roberts · Director John R. Stuelpnagel · Director Roger T. Wyse · Director Andrew D. Garst · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “The Total Offering Amount and Total Amount Sold represent the aggregate exercise price of certain options to purchase shares of Common Stock of the Issuer.”Signed by Kevin D. Ness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 7, 2018. Read the notice at the SEC .
options SEC Apr 2016 $6 M No. 1 $2 to $10 million 2
Muse Biotechnology, Inc.: Raise no. 1, Apr 2016 × Investors in this round 2 investors had bought by the notice of May 11, 2016: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $6 M of $6 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ryan T. Gill · Executive Officer, Director, Promoter Tanya T. Lipscomb · Executive Officer, Director, Promoter Eric T. Moessinger · Director Roger T. Wyse · Director Andrew D. Garst · Promoter Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Ryan T. Gill, President and Chief Executive Officer. Source: SEC Form D, newest notice filed May 11, 2016. Read the notice at the SEC .
equity SEC